Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
IPhEB Russia
Not Confirmed
Contact SupplierIPhEB Russia
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content
NEWS #PharmaBuzz
19 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/19/3258948/0/en/Grace-Therapeutics-to-Present-Data-on-the-Unmet-Medical-Needs-and-Potential-Benefits-of-GTx-104-in-the-Treatment-of-aSAH-at-Upcoming-Medical-Conferences.html
25 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/25/3244527/0/en/Grace-Therapeutics-to-Participate-in-the-TD-Cowen-46th-Annual-Health-Care-Conference.html
12 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/12/3237136/0/en/Grace-Therapeutics-Announces-Third-Quarter-2026-Financial-Results-Provides-Business-Update.html
17 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/17/3189080/0/en/Grace-Therapeutics-to-Participate-in-16th-Annual-Craig-Hallum-Alpha-Select-Conference.html
13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187283/0/en/Grace-Therapeutics-Announces-Second-Quarter-2026-Financial-Results-Provides-Business-Update.html
11 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/11/3185406/0/en/Grace-Therapeutics-Announces-Abstract-Accepted-for-Presentation-at-Society-of-Vascular-and-Interventional-Neurology-Annual-Meeting.html
Drugs in Development
Details:
In a private placement deal, Nimodipine will be funded to support the clinical development for aneurysmal subarachnoid hemorrhage.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: GTx-104
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 23, 2025
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $4.0 million
Deal Type : Private Placement
Grace Therapeutics Raises $4.0M for GTx-104 FDA Review
Details : In a private placement deal, Nimodipine will be funded to support the clinical development for aneurysmal subarachnoid hemorrhage.
Product Name : GTx-104
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 23, 2025
Details:
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Grace Aligns with FDA on NDA Submission Plan for GTx-104
Details : GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2025
Details:
GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2025
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Grace Therapeutics Reports Phase 3 STRIVE-ON Trial Results for GTx-104
Details : GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2025
Details:
The proceeds from the financing will used to fund the development of company's lead poduct GTx-104 (nimodipine), which is being evaluated for the treatment of Aneurysmal Subarachnoid Hemorrhage.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Nantahala Capital Management
Deal Size: $30.0 million Upfront Cash: $15.0 million
Deal Type: Private Placement February 10, 2025
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Nantahala Capital Management
Deal Size : $30.0 million
Deal Type : Private Placement
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Details : The proceeds from the financing will used to fund the development of company's lead poduct GTx-104 (nimodipine), which is being evaluated for the treatment of Aneurysmal Subarachnoid Hemorrhage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $15.0 million
February 10, 2025
Details:
GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2024
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acasti Completes Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Details : GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Details:
GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2024
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Details : GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2024
Details:
GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 23, 2023
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 23, 2023
Details:
The company currently intends to use the net proceeds for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 26, 2023
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $7.5 million
Deal Type : Private Placement
Acasti Announces $7.5 Million Private Placement Equity Financing
Details : The company currently intends to use the net proceeds for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 26, 2023
Details:
GTX-104 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Subarachnoid Hemorrhage.
Lead Product(s): GTX-104
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2023
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Details : GTX-104 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Subarachnoid Hemorrhage.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Details:
GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.
Lead Product(s): Nimodipine
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2023
Lead Product(s) : Nimodipine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
